ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society.

PubWeight™: 3.52‹?› | Rank: Top 1%

🔗 View Article (PMID 16987906)

Published in Europace on September 01, 2006

Authors

Valentin Fuster1, Lars E Rydén, David S Cannom, Harry J Crijns, Anne B Curtis, Kenneth A Ellenbogen, Jonathan L Halperin, Jean-Yves Le Heuzey, G Neal Kay, James E Lowe, S Bertil Olsson, Eric N Prystowsky, Juan Luis Tamargo, Samuel Wann, Sidney C Smith, Alice K Jacobs, Cynthia D Adams, Jeffery L Anderson, Elliott M Antman, Jonathan L Halperin, Sharon Ann Hunt, Rick Nishimura, Joseph P Ornato, Richard L Page, Barbara Riegel, Silvia G Priori, Jean-Jacques Blanc, Andrzej Budaj, A John Camm, Veronica Dean, Jaap W Deckers, Catherine Despres, Kenneth Dickstein, John Lekakis, Keith McGregor, Marco Metra, Joao Morais, Ady Osterspey, Juan Luis Tamargo, José Luis Zamorano, American College of Cardiology, American Heart Association Task Force, European Society of Cardiology Committee for Practice Guidelines, European Heart Rhythm Association, Heart Rhythm Society

Author Affiliations

1: France.

Associated clinical trials:

Time-dependent Amiodarone Treatment in Atrial Fibrillation | NCT03432663

Articles citing this

(truncated to the top 100)

Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ (2011) 5.84

The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med (2009) 4.71

Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: barriers to and strategies for optimal implementation. Europace (2015) 1.98

Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. Eur Heart J (2014) 1.50

Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation. Europace (2010) 1.43

Effect of dronedarone on clinical end points in patients with atrial fibrillation and coronary heart disease: insights from the ATHENA trial. Europace (2013) 1.42

Chronic obstructive pulmonary disease and the risk of cardiovascular diseases. Eur J Epidemiol (2010) 1.41

Warfarin discontinuation after starting warfarin for atrial fibrillation. Circ Cardiovasc Qual Outcomes (2010) 1.39

Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol (2014) 1.39

Update on anti-coagulation in atrial fibrillation. QJM (2011) 1.28

Quality and safety of medication use in primary care: consensus validation of a new set of explicit medication assessment criteria and prioritisation of topics for improvement. BMC Clin Pharmacol (2012) 1.22

Withdrawal of antithrombotic agents and its impact on ischemic stroke occurrence. Stroke (2011) 1.17

Prior antiarrhythmic drug use and the outcome of atrial fibrillation ablation. Europace (2012) 1.13

Significant association of SNP rs2106261 in the ZFHX3 gene with atrial fibrillation in a Chinese Han GeneID population. Hum Genet (2010) 1.09

The role of the renin-angiotensin system in atrial fibrillation and the therapeutic effects of ACE-Is and ARBS. Br J Clin Pharmacol (2008) 1.01

Acupuncture for paroxysmal and persistent atrial fibrillation: An effective non-pharmacological tool? World J Cardiol (2012) 0.98

Obesity, diabetes and atrial fibrillation; epidemiology, mechanisms and interventions. Curr Cardiol Rev (2012) 0.98

High-rate pacing-induced atrial fibrillation effectively reveals properties of spontaneously occurring paroxysmal atrial fibrillation in humans. Europace (2012) 0.96

Risks for stroke and bleeding with warfarin or aspirin treatment in patients with atrial fibrillation at different CHA(2)DS(2)VASc scores: experience from the Stockholm region. Eur J Clin Pharmacol (2014) 0.91

Atrial fibrillation: the cost of illness in Sweden. Eur J Health Econ (2010) 0.91

Surgery for atrial fibrillation. Nat Rev Cardiol (2009) 0.90

Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy. Eur Heart J (2010) 0.89

Dronedarone: current evidence for its safety and efficacy in the management of atrial fibrillation. Drug Des Devel Ther (2011) 0.89

Effect of cardiovascular drug classes on all-cause mortality among atrial fibrillation patients treated in primary care in Sweden: a cohort study. Eur J Clin Pharmacol (2012) 0.89

Isoform specificity of cardiac glycosides binding to human Na+,K+-ATPase alpha1beta1, alpha2beta1 and alpha3beta1. Eur J Pharmacol (2009) 0.88

Antioxidant vitamins in the prevention of atrial fibrillation: what is the evidence? Cardiol Res Pract (2011) 0.88

SNP rs3825214 in TBX5 is associated with lone atrial fibrillation in Chinese Han population. PLoS One (2013) 0.88

Intracardiac atrial defibrillation. Heart Rhythm (2006) 0.86

A randomized trial of the safety, pharmacokinetics and pharmacodynamics of edoxaban, an oral factor Xa inhibitor, following a switch from warfarin. Br J Clin Pharmacol (2013) 0.85

The worldwide social burden of atrial fibrillation: what should be done and where do we go? J Interv Card Electrophysiol (2007) 0.84

Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents. Europace (2012) 0.84

Renal denervation: effects on atrial electrophysiology and arrhythmias. Clin Res Cardiol (2014) 0.84

Clinical epidemiology of atrial fibrillation and related cerebrovascular events in the United States. Neurologist (2008) 0.83

Atrial fibrillation and heart failure in the elderly. Heart Fail Rev (2012) 0.83

Short-term ECG recordings for heart rate assessment in patients with chronic atrial fibrillation. Arch Med Sci (2014) 0.82

The natural history of atrial fibrillation in patients with permanent pacemakers: is atrial fibrillation a progressive disease? J Interv Card Electrophysiol (2015) 0.81

Plasma fibulin-1 is linked to restrictive filling of the left ventricle and to mortality in patients with aortic valve stenosis. J Am Heart Assoc (2012) 0.81

Can we improve outcomes in AF patients by early therapy? BMC Med (2009) 0.81

Left atrial appendage exclusion-Where do we stand? J Thorac Dis (2014) 0.80

New X-ray imaging modalities and their integration with intravascular imaging and interventions. Int J Cardiovasc Imaging (2009) 0.80

Optimisation of ionic models to fit tissue action potentials: application to 3D atrial modelling. Comput Math Methods Med (2013) 0.80

Effects of prescribed antithrombotics and other cardiovascular pharmacotherapies on all-cause mortality in patients with diabetes and atrial fibrillation - a cohort study from Sweden using propensity score analyses. Diabetol Metab Syndr (2014) 0.80

Pharmacological management of atrial fibrillation: one, none, one hundred thousand. Cardiol Res Pract (2011) 0.80

Anti-NMDA receptor encephalitis associated with atrial fibrillation and hearing loss. Neurol Neuroimmunol Neuroinflamm (2014) 0.79

QT variability during initial exposure to sotalol: experience based on a large electronic medical record. Europace (2013) 0.79

Association between reversal in the expression of hyperpolarization-activated cyclic nucleotide-gated (HCN) channel and age-related atrial fibrillation. Med Sci Monit (2014) 0.79

An Observational, Prospective Survey Assessing the Control of Atrial Fibrillation in Asia Pacific: Rationale and Design of the RecordAF-AP Registry. Clin Med Insights Cardiol (2011) 0.78

Pulmonary venous isolation versus additional substrate modification as treatment for paroxysmal atrial fibrillation. J Interv Card Electrophysiol (2011) 0.78

Novel approaches for the surgical treatment of atrial fibrillation: time for a guideline revision? Vasc Health Risk Manag (2010) 0.78

Clinical characteristics, management, and control of permanent vs. nonpermanent atrial fibrillation: insights from the RealiseAF survey. PLoS One (2014) 0.78

Phase synchrony reveals organization in human atrial fibrillation. Am J Physiol Heart Circ Physiol (2015) 0.78

Multiple thromboembolism with multiple causes in a 69-year-old woman: a case report. J Med Case Rep (2011) 0.78

Esophageal injury after atrial fibrillation ablation with an epicardial high-intensity focused ultrasound device. J Interv Card Electrophysiol (2011) 0.78

Effect of dronedarone on exercise capacity and cardiac function in patients with severe left ventricular dysfunction and compensated stable heart failure. Cardiovasc Drugs Ther (2010) 0.78

Contemporary management of atrial fibrillation: what can clinical registries tell us about stroke prevention and current therapeutic approaches? J Am Heart Assoc (2014) 0.78

Stroke risk associated with balloon based catheter ablation for atrial fibrillation: Rationale and design of the MACPAF Study. BMC Neurol (2010) 0.77

Altered expression of hyperpolarization-activated cyclic nucleotide-gated channels and microRNA-1 and -133 in patients with age-associated atrial fibrillation. Mol Med Rep (2015) 0.77

Managing atrial fibrillation in the very elderly patient: challenges and solutions. Vasc Health Risk Manag (2015) 0.77

Intracardiac echocardiography in electrophysiology. Herzschrittmacherther Elektrophysiol (2007) 0.77

Atrial fibrillation and revascularization procedures: clinical and prognostic significance. Incidence, predictors, treatment, and long-term outcome. Indian Pacing Electrophysiol J (2007) 0.77

Use of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Lesions. J Am Heart Assoc (2016) 0.77

Does minimal-access aortic valve replacement reduce the incidence of postoperative atrial fibrillation? Tex Heart Inst J (2008) 0.77

Contrast enhanced transesophageal echocardiography in patients with atrial fibrillation referred to electrical cardioversion improves atrial thrombus detection and may reduce associated thromboembolic events. Cardiovasc Ultrasound (2013) 0.76

Trends in the management of atrial fibrillation: A neurologist's perspective. J Cardiovasc Dis Res (2012) 0.76

Identification of rare variants in TNNI3 with atrial fibrillation in a Chinese GeneID population. Mol Genet Genomics (2015) 0.76

A net clinical benefit analysis of warfarin and aspirin on stroke in patients with atrial fibrillation: a nested case-control study. BMC Cardiovasc Disord (2012) 0.76

The impact of gender and left atrial blood stasis on adiponectin levels in non-valvular atrial fibrillation. Int J Cardiol (2014) 0.76

Towards Low Energy Atrial Defibrillation. Sensors (Basel) (2015) 0.75

Use of vitamin K antagonists for secondary stroke prevention depends on the treating healthcare provider in Germany - results from the German AFNET registry. BMC Neurol (2015) 0.75

Atrial pacing for rhythm control of atrial fibrillation. Neth Heart J (2008) 0.75

Atorvastatin Treatment for Atrial Fibrillation Reduces Serum High-Sensitivity C-Reactive Protein Levels. Biomed Res Int (2015) 0.75

Catheter Ablation Of Atrial Fibrillation In The Elderly: Risk Benefit Analysis. J Atr Fibrillation (2014) 0.75

Risk Stratification in Atrial Fibrillation Patients - A Review Focused on Mortality. Arrhythm Electrophysiol Rev (2012) 0.75

Preventing stroke in atrial fibrillation patients - clinical utility of oral anticoagulants. J Blood Med (2012) 0.75

The Role of Three-dimensional Rotational Angiography in Atrial Fibrillation Ablation. Arrhythm Electrophysiol Rev (2013) 0.75

Kidney dysfunction and cerebral microbleeds in neurologically healthy adults. PLoS One (2017) 0.75

Some patients with paroxysmal atrial fibrillation should carry flecainide or propafenone to self treat. BMJ (2007) 0.75

Determining conduction patterns on a sparse electrode grid: Implications for the analysis of clinical arrhythmias. Phys Rev E (2016) 0.75

Predictors of atrial fibrillation recurrence in patients with long-lasting atrial fibrillation. Can J Cardiol (2009) 0.75

An evidence-based review of apixaban and its potential in the prevention of stroke in patients with atrial fibrillation. Core Evid (2012) 0.75

Rs7193343 polymorphism in zinc finger homeobox 3 (ZFHX3) gene and atrial fibrillation: an updated meta-analysis of 10 case-control comparisons. BMC Cardiovasc Disord (2015) 0.75

An International Observational Prospective Survey Assessing the Control of Atrial Fibrillation in Asia-Pacific: Results of the Record-AFAP Registry. Clin Med Insights Cardiol (2015) 0.75

Preserving Cognitive Function in Patients with Atrial Fibrillation. J Atr Fibrillation (2014) 0.75

Update of secondary stroke prevention. Nephrol Dial Transplant (2009) 0.75

Underutilization of Warfarin Therapy in Elderly Patients with Atrial Fibrillation - Fear or False Sense of Security! J Atr Fibrillation (2008) 0.75

Atrial fibrillation associated with a thyroid stimulating hormone-secreting adenoma of the pituitary gland leading to a presentation of acute cardiac decompensation: a case report. J Med Case Rep (2008) 0.75

Dietary Fat Intake Is Differentially Associated with Risk of Paroxysmal Compared with Sustained Atrial Fibrillation in Women. J Nutr (2015) 0.75

Long-term outcomes after ablation of persistent atrial fibrillation: an observational study over 6 years. Open Heart (2016) 0.75

Case 4: 84-year old female with precordial pain and cardiac arrest with pulseless electrical activity. Arq Bras Cardiol (2013) 0.75

Electrocardiographic findings in patients with polycythemia vera. Int J Med Sci (2011) 0.75

Is self-monitoring an effective option for people receiving long-term vitamin K antagonist therapy? A systematic review and economic evaluation. BMJ Open (2015) 0.75

Regularization Techniques for ECG Imaging during Atrial Fibrillation: A Computational Study. Front Physiol (2016) 0.75

Hyperthermia Influences the Effects of Sodium Channel Blocking Drugs in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes. PLoS One (2016) 0.75

Relaxin Level in Patients With Atrial Fibrillation and Association with Heart Failure Occurrence: A STROBE Compliant Article. Medicine (Baltimore) (2016) 0.75

Electrocardiogram PR Interval Is a Surrogate Marker to Predict New Occurrence of Atrial Fibrillation in Patients with Frequent Premature Atrial Contractions. J Korean Med Sci (2016) 0.75

Bone Morphogenetic Protein-7 Antagonizes Myocardial Fibrosis Induced by Atrial Fibrillation by Restraining Transforming Growth Factor-β (TGF-β)/Smads Signaling. Med Sci Monit (2016) 0.75

Atrial fibrillation: state of the art. Wien Klin Wochenschr (2014) 0.75

Submuscular implantation of insertable cardiac monitors improves the reliability of detection of atrial fibrillation. J Interv Card Electrophysiol (2015) 0.75

[Medicinal rate control in atrial fibrillation]. Herzschrittmacherther Elektrophysiol (2014) 0.75

[Stroke and atrial fibrillation]. Herzschrittmacherther Elektrophysiol (2009) 0.75

Articles by these authors

Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation (2005) 43.74

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet (2004) 42.12

Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation (2009) 35.24

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99

Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med (2002) 27.55

Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation (2003) 23.97

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation (2004) 23.07

Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation (2002) 21.38

Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation (2004) 20.67

2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2007) 20.09

Particulate matter air pollution and cardiovascular disease: An update to the scientific statement from the American Heart Association. Circulation (2010) 19.30

ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation (2005) 18.90

ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J (2012) 18.18

Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2009) 18.03

Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2007) 17.85

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 17.18

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2013) 16.52

Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J (2010) 16.39

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J (2012) 16.00

Scientific evidence underlying the ACC/AHA clinical practice guidelines. JAMA (2009) 13.69

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet (2008) 13.34

ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation (2006) 13.21

Air pollution and cardiovascular disease: a statement for healthcare professionals from the Expert Panel on Population and Prevention Science of the American Heart Association. Circulation (2004) 13.07

2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73

Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med (2009) 12.44

Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer. Eur Heart J (2009) 11.90

2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 11.88

Universal definition of myocardial infarction. Circulation (2007) 11.69

ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation (2006) 11.49